Insider Transactions in Q1 2021 at Aclaris Therapeutics, Inc. (ACRS)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
7,500
-6.14%
|
-
|
|
Mar 02
2021
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,982
-0.65%
|
$183,586
$23.25 P/Share
|
|
Mar 02
2021
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,253
+1.46%
|
-
|
|
Mar 02
2021
|
Frank Ruffo Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,844
-1.18%
|
$65,412
$23.25 P/Share
|
|
Mar 02
2021
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,297
+3.32%
|
-
|
|
Mar 02
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,906
-1.31%
|
$43,838
$23.25 P/Share
|
|
Mar 02
2021
|
Kamil Ali Jackson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,637
+4.36%
|
-
|
|
Mar 02
2021
|
David N. Gordon Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,280
-2.06%
|
$52,440
$23.25 P/Share
|
|
Mar 02
2021
|
David N. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,297
+6.97%
|
-
|
|
Mar 01
2021
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
39,792
-3.18%
|
$955,008
$24.06 P/Share
|
|
Mar 01
2021
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
96,150
+7.13%
|
-
|
|
Mar 01
2021
|
Frank Ruffo Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,333
-3.04%
|
$175,992
$24.06 P/Share
|
|
Mar 01
2021
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,750
+9.66%
|
-
|
|
Mar 01
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,934
-3.43%
|
$118,416
$24.06 P/Share
|
|
Mar 01
2021
|
Kamil Ali Jackson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,175
+10.67%
|
-
|
|
Mar 01
2021
|
David N. Gordon Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,660
-5.23%
|
$135,840
$24.06 P/Share
|
|
Mar 01
2021
|
David N. Gordon Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,600
+16.0%
|
-
|
|
Feb 02
2021
|
Anand Mehra |
BUY
Exercise of conversion of derivative security
|
Direct |
14,632
+21.27%
|
$263,376
$18.34 P/Share
|
|
Feb 01
2021
|
Neal Walker INTERIM CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,316
-0.29%
|
$69,636
$21.35 P/Share
|
|
Feb 01
2021
|
Neal Walker INTERIM CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,800
+0.92%
|
-
|
|
Feb 01
2021
|
Kamil Ali Jackson Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,318
-1.03%
|
$27,678
$21.35 P/Share
|
|
Feb 01
2021
|
Kamil Ali Jackson Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+2.94%
|
-
|
|
Feb 01
2021
|
Frank Ruffo Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-0.6%
|
$27,468
$21.35 P/Share
|
|
Feb 01
2021
|
Frank Ruffo Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,875
+1.76%
|
-
|